期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 63, 期 8, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00614-19
关键词
beta-lactams; Mycobacterium abscessus; synergy
资金
- Cystic Fibrosis Foundation award [LAMICH17GO]
- National Institutes of Health [R21 AI137720]
- NIH [T32 AI007291]
Mycobacterium abscessus is an emerging pathogen capable of causing invasive pulmonary infections in patients with chronic lung diseases. These infections are difficult to treat, necessitating prolonged multidrug therapy, which is further complicated by extensive intrinsic and acquired resistance exhibited by clinical M. abscessus isolates. Therefore, development of novel treatment regimens effective against drug-resistant strains is crucial. Prior studies have demonstrated synergistic efficacy of several beta-lactams against M. abscessus in vitro; however, these combinations have never been tested in an animal model of M. abscessus pulmonary disease. We utilized a recently developed murine system of sustained M. abscessus lung infection delivered via an aerosol route to test the bactericidal efficacy of four novel dual beta-lactam combinations and one beta-lactam/beta-lactamase inhibitor combination. All five of the novel combinations exhibited synergy and resulted in at least 6-log(10) reductions in bacterial burden in the lungs of mice at 4 weeks compared to untreated controls (P = 0.038).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据